Phase II study of oral VP-16-213 in hepatocellular carcinoma
- 1 October 1981
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 17 (10) , 1079-1082
- https://doi.org/10.1016/0014-2964(81)90291-7
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- A phase II study of neocarzinostatin (NSC 157365) in malignant hepatomaCancer Chemotherapy and Pharmacology, 1980
- Chemotherapy studies in primary liver cancer. A prospective randomized clinical trialCancer, 1978
- INDUCTION OF REMISSION IN HEPATOCELLULAR CARCINOMA WITH DOXORUBICINThe Lancet, 1978
- Quadruple chemotherapy versus radiotherapy in treatment of primary hepatocellular carcinomaCancer, 1977
- VM 26 and VP 16–213: A comparative analysisCancer, 1977
- A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United StatesCancer, 1977
- Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cellsBiochemistry, 1976
- Treatment of hepatocellular carcinoma with adriamycin.Preliminary communicationCancer, 1975
- Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumorsPublished by Elsevier ,1973
- Survival after liver resection for cancerCancer, 1970